SNDX Q2 2024 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

$4M100.0% margin

Operating Income

-$74M-2120.5% margin

Net Income

-$68M-1944.7% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$72M

Free Cash Flow

-$72M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$477M

Total Liabilities

$43M

Stockholders' Equity

$434M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	$4M	$0	—
Operating Income	-$74M	-$50M	-49.4%
Net Income	-$68M	-$45M	-52.6%